Science in Sport is targeting its share of a reported £19.6 billion global market in 2010 by securing a stock market listing.
Private equity firm Graphite Capital has followed up on its recent investment in the Hawksmoor chain of restaurants by exiting its interest in Willowbrook Healthcare.
The Biomedical Catalyst is allocating £25.9 million as part of a new support package for businesses and academic projects in the health industry.
The Seed Enterprise Investment Scheme (SEIS) has allowed biotechnology business Oxford Genetics to net £150,000 of new funding.
The North West Fund for Biomedical and Fusion IP are coming together to back the growth ambition of University of Sheffield spin-out Absynth Biologics.
A £250,000 investment led North West Fund for Biomedical will be used by Tomorrows Medicines to commercialise its new platform.
Private equity firm ECI Partners has sold its stake in CliniSys and netted a 2.5x return on its 2007 investment.
Venture capital firm Atomico has stepped up to lead a $10 million investment into ChemistDirect.
AIM-listed investment firm Imperial Innovations Group has secured a £30 million loan so that it can make investments in the biotech and therapeutics sectors.
A thirty one-year old specialist furniture business has taken on private equity backing as it looks to grow through organic and acquisitive means.
The £25 million North West Fund for Biomedical has made its 57th investment to date through the backing of Perfectus Biomed.
An $11 million investment from Index Ventures will be used to develop an anticoagulant drug aimed at preventing heart attacks and strokes without causing bleeding.
Growth Capital Partners portfolio company Fishawack has completed its first acquisition since the private equity firm backed a secondary buy-out at the company back in March.
A new collaboration between Alliance Boots and BioCity will see the creation of a new business incubator focused on health and wellness.
Octopus Investments has led a £2 million investment into clinical trials platform TrialReach alongside Amadeus Capital Partners.
Cerus Endovascular is moving its operations to Liverpool Science Park following backing from The North West Fund for Biomedical.
Care home operator Springfield Healthcare Group has already begun to use its Business Growth Fund cash to get acquisitive. We find out how progress has been since the investment as part of an exclusive portfolio roundtable.
Neuropsychological testing business Cambridge Cognition has joined London's Alternative Investment Market.
Business Growth Fund portfolio company Springfield Homecare Services has closed its first acquisition since the business was supported by the bank-backed fund in June 2012.
The private equity firm behind investments in Wagamama and Paperchase has sold its stake in Optimum Care through a trade sale.
At the beginning of 2013 Richard Reed and the rest of his founding team at Innocent Drinks sold out the last of their stake to Coca Cola. GrowthBusiness finds out what happens after exiting a business valued at $500 million.
Glenn Porter, general manager international identity verification at GBGroup, examines the opportunities and risks of trading with the MINT population of Mexico, Indonesia, Nigeria and Turkey.
With March IPOs raising £671 million on London's AIM market, it looks like the junior exchange is back to its best.